ERBB2 and gastric cancer: Since the collection of this data in 2019, 1L treatment comprised of a combination of nivolumab plus chemotherapy has recently been approved by the European Commission for use in patients with HER2 negative advanced or metastatic GC, GEJ, or EAC [31].